Roche’s MabThera (rituximab) Receives EU’s Approval for Rare Autoimmune Disease Pemphigus Vulgaris (PV)

 Roche’s MabThera (rituximab) Receives EU’s Approval for Rare Autoimmune Disease Pemphigus Vulgaris (PV)

Roche’s MabThera (rituximab) Receives EU’s Approval for Rare Autoimmune Disease Pemphigus Vulgaris (PV)

Shots:

  • The EU approval is based on P-III Ritux 3 study assessing MabThera + oral Corticosteroids (CS) vs CS as monothx.in patients with 1L moderate to severe pemphigus vulgaris (PV) in France
  • The P-III Ritux 3 study results: met its 1EPs; achieved complete remission @24mos.; remission @2mos. (89.5% vs 27.8%); published in The Lancet in Mar’17
  • MabThera (Rituxan in the US) is a novel mAb target cancer cells with CD20 marker on their surface in patients with severe active RA in combination with methotrexate and is approved in the US in Jun’18 for PV

Click here to read full press release/ article | Ref: Roche | Image: Top Employers Institute

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post